13.09.2024 16:17:08
|
Novavax Says Its COVID-19 Vaccine 2024-2025 Formula Now Available At Major Pharmacies Nationwide
(RTTNews) - Novavax, Inc. (NVAX) announced Friday that doses of the Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) (NVX-CoV2705) to prevent COVID-19 in individuals aged 12 and older are in stock at major pharmacy retailers across the U.S.
Through agreements with pharmacies, Novavax's updated vaccine is expected to be widely available in locations including, but not limited to, CVS Pharmacy, Rite Aid, Walgreens, Costco, Publix, Sam's Club, Kroger, Meijer, hundreds of other regional grocers and thousands of independent pharmacies.
Novavax's updated vaccine received Emergency Use Authorization (EUA) on August 30, 2024 from the U.S. Food and Drug Administration (FDA). The EUA of this product will remain in effect for the duration of the COVID-19 EUA declaration justifying emergency use of the product, unless the authorization is revoked sooner.
Novavax's vaccine is the only protein-based option available in the U.S. this fall and is in pre-filled syringe presentation.
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Novavax Inc.mehr Nachrichten
11.11.24 |
Ausblick: Novavax präsentiert das Zahlenwerk zum abgelaufenen Jahresviertel (finanzen.net) | |
08.08.24 |
Umsatz von Novavax fällt deutlich - Novavax-Aktie dennoch höher (finanzen.at) | |
07.08.24 |
Ausblick: Novavax zieht Bilanz zum jüngsten Jahresviertel (finanzen.net) |
Analysen zu Novavax Inc.mehr Analysen
Aktien in diesem Artikel
Novavax Inc. | 8,31 | -4,15% |